Bristol-Myers Squibb (BMY) 주식 개요
브리스톨-마이어스 스퀴브 컴퍼니는 전 세계에서 바이오 의약품을 발굴, 개발, 허가, 제조, 마케팅, 유통 및 판매하는 기업입니다. 자세히 보기
BMY Community Fair Values
Create NarrativeSee what 341 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$65
FV
0.5% 고평가 내재 할인율713
users have viewed this narrative3users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
Bristol-Myers Squibb Company 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$65.31 |
| 52주 최고가 | US$65.66 |
| 52주 최저가 | US$42.52 |
| 베타 | 0.24 |
| 1개월 변동 | 15.72% |
| 3개월 변동 | 12.18% |
| 1년 변동 | 47.66% |
| 3년 변동 | 7.97% |
| 5년 변동 | -4.13% |
| IPO 이후 변동 | 2,956.56% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 31
BMY: Q2 Execution And Late Stage Pipeline Will Drive Re Rating
Analysts have lifted the fair value estimate for Bristol-Myers Squibb to $80 from $75, citing recent price target increases into the low to mid $70s and a consistent focus on the company's Q2 results and pipeline potential as key factors supporting the updated view. Analyst Commentary Recent Street research on Bristol-Myers Squibb highlights a cluster of higher price targets following Q2 results.Seeking Alpha • Jul 30
Bristol Myers Squibb: Upgrading To Buy On Positive Q2 Earnings, Long-Term Outlook
Summary Bristol Myers Squibb delivered strong Q2 2026 results, with revenue and EPS both exceeding expectations and robust cash flow performance. BMY’s forward P/E of ~9.2x and P/S of ~2.6x, combined with a ~4% dividend yield, suggest the stock is undervalued versus Big Pharma peers. While legacy portfolio revenues decline due to patent expiries, the growth portfolio is gaining traction, though some assets have underperformed expectations. I upgrade BMY to Buy, citing a promising late-stage pipeline and confidence that new launches will offset Eliquis’s eventual revenue loss. Read the full article on Seeking AlphaRecent updates
내러티브 업데이트 • Jul 31
BMY: Q2 Execution And Late Stage Pipeline Will Drive Re Rating
Analysts have lifted the fair value estimate for Bristol-Myers Squibb to $80 from $75, citing recent price target increases into the low to mid $70s and a consistent focus on the company's Q2 results and pipeline potential as key factors supporting the updated view. Analyst Commentary Recent Street research on Bristol-Myers Squibb highlights a cluster of higher price targets following Q2 results.Seeking Alpha • Jul 30
Bristol Myers Squibb: Upgrading To Buy On Positive Q2 Earnings, Long-Term Outlook
Summary Bristol Myers Squibb delivered strong Q2 2026 results, with revenue and EPS both exceeding expectations and robust cash flow performance. BMY’s forward P/E of ~9.2x and P/S of ~2.6x, combined with a ~4% dividend yield, suggest the stock is undervalued versus Big Pharma peers. While legacy portfolio revenues decline due to patent expiries, the growth portfolio is gaining traction, though some assets have underperformed expectations. I upgrade BMY to Buy, citing a promising late-stage pipeline and confidence that new launches will offset Eliquis’s eventual revenue loss. Read the full article on Seeking Alpha내러티브 업데이트 • Jun 16
BMY: Late Stage Pipeline Wins And Policy Risks Will Drive Re Rating
Analysts slightly revised their average price target for Bristol-Myers Squibb stock, reflecting updated views on a modestly softer revenue outlook, stable fair value near $75.00, and largely unchanged long term margin and P/E assumptions following recent commentary on Medicare negotiation risk. Analyst Commentary Bristol-Myers Squibb continues to attract mixed but constructive attention from Wall Street, with recent notes focusing on Medicare negotiation risk, price target fine-tuning, and how current valuation lines up with long term earnings power.분석 기사 • Jun 16
Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion
Bristol-Myers Squibb (BMY) stock is back in focus after the company expanded its kidney cancer trial through a clinical collaboration with Arcus Biosciences, adding new casdatifan arms to the ROSETTA RCC-208 study. See our latest analysis for Bristol-Myers Squibb. The kidney cancer trial expansion comes after a mixed period for Bristol-Myers Squibb, with the share price at $56.24, a year to date share price return of 5.2%, and a 1 year total shareholder return of 21.35%. This suggests...내러티브 업데이트 • Jun 02
BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating
Analysts have raised the average Bristol-Myers Squibb price target by a few dollars, citing a series of recent upward revisions into the $60 to $70 range. These revisions reflect ongoing debate around macro risks, healthcare sector positioning, and upcoming Milvexian Phase III data.
내러티브 업데이트 • May 18
BMY: Pipeline Execution And Macro Shifts Will Shape Future Risk Balance
Analysts now see Bristol-Myers Squibb’s fair value edging down by $0.08 to $62.96, as they factor in slightly weaker revenue growth and profit margin assumptions alongside a higher future P/E, even as recent Street price target moves reflect mixed views on the stock’s pipeline and macro setup. Analyst Commentary Recent Street commentary on Bristol-Myers Squibb highlights a wide range of views on execution risk, pipeline delivery and how those factors may feed into valuation over the next few years.내러티브 업데이트 • May 03
BMY: Upcoming Late Stage Readouts Will Drive Potential Re Rating Opportunity
Analysts have made only a modest adjustment to their Bristol-Myers Squibb outlook, with small changes to revenue and profitability assumptions feeding into updated price targets that cluster in a wide range from about $60 to $75. This reflects differing views on the pipeline and upcoming Milvexian data as potential drivers for the story.내러티브 업데이트 • Apr 19
BMY: Pipeline Progress And Sector Shifts Will Shape Future Risk Balance
Analysts have raised the implied fair value for Bristol-Myers Squibb to $63.04 from $59.91, reflecting a series of recent price target increases based on slightly less severe revenue contraction expectations, a modest improvement in projected profit margins, and support from pipeline-related research updates across multiple firms. Analyst Commentary Recent research has focused on how Bristol-Myers Squibb balances patent expirations on key products with progress in its pipeline and late stage programs, and how that mix feeds into valuation, execution risk, and potential growth beyond current revenue headwinds.
내러티브 업데이트 • Apr 04
BMY: 2026 Catalyst Calendar Will Likely Fail To Offset Patent Cliff
Analyst price targets for Bristol-Myers Squibb have moved higher into a broad $60 to $75 range, with analysts pointing to a rich 2026 catalyst calendar, emerging pipeline readouts such as milvexian Phase III data, and relatively lower exposure to AI disruption risks as key supports for the updated views. Analyst Commentary Recent research highlights a mix of optimism and caution around Bristol-Myers Squibb, with the Street focusing on a packed 2026 catalyst calendar, milvexian Phase III data, and a broad set of late stage assets.내러티브 업데이트 • Mar 21
BMY: 2026 Late Stage Pipeline Catalysts Will Likely Limit Further Upside
The analyst price target for Bristol Myers Squibb has moved higher, with the fair value estimate shifting from $40.67 to $45.67 as analysts point to a richer pipeline of late stage catalysts, a higher projected profit margin, and sector wide support from the appeal of healthcare during a choppy macro backdrop. Analyst Commentary Recent research coverage on Bristol Myers Squibb has tilted more constructive, with several firms lifting price targets into the US$60 to US$75 range and highlighting a dense calendar of late stage readouts through 2026.내러티브 업데이트 • Mar 06
BMY: 2026 Late-Stage Pipeline Readouts Will Shape Re-Rating Potential
Analysts have lifted their Bristol Myers Squibb fair value estimate from $68.00 to $75.00, citing higher Street price targets and an increased focus on pipeline catalysts such as the Phase III milvexian data and a dense slate of 2026 readouts. Analyst Commentary Recent Street research on Bristol Myers Squibb clusters around a more constructive view of the pipeline, especially the 2026 readout slate and the Phase III milvexian program, with several firms revisiting their valuation frameworks in light of these potential catalysts.내러티브 업데이트 • Feb 20
BMY: 2026 Pipeline Catalysts And Sector Recovery Will Shape Risk Balance
Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to about $60. This reflects how recent price target increases and generally constructive research commentary around the pipeline are starting to offset concerns about upcoming patent expirations.분석 기사 • Feb 18
We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit
Bristol-Myers Squibb Company ( NYSE:BMY ) announced a healthy earnings result recently, and the market rewarded it with...내러티브 업데이트 • Feb 06
BMY: 2026 Pipeline Readouts And Sector Recovery Will Guide Next Repricing
Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to US$58.13 from US$56.26. This reflects updated Street research in which analysts cite a richer mix of potential 2026 pipeline catalysts and a slightly higher assumed future P/E multiple, both of which support recent price target increases across several firms.내러티브 업데이트 • Jan 23
BMY: 2026 Pipeline Readouts Will Likely Cap Near Term Upside
Analysts have lifted their blended price target on Bristol Myers Squibb by roughly US$2 to reflect higher estimated fair value and profitability, citing a rich set of 2026 pipeline readouts and what they view as underappreciated upside in several late-stage assets. Analyst Commentary Recent Street research on Bristol Myers Squibb points to a mixed but generally constructive stance, with several firms lifting price targets into the US$53 to US$65 range and highlighting what they see as meaningful 2026 data catalysts across eight late stage assets.내러티브 업데이트 • Jan 08
BMY: Sector Tailwinds And Pipeline Milestones Will Shape Next Share Rerating
Analysts have nudged their price targets for Bristol Myers Squibb higher, with moves such as UBS shifting to a Buy rating with a US$65 target from US$46 and Citi lifting its target to US$53 from US$45. This reflects growing confidence tied to sector tailwinds, improving deal activity, and a refreshed view of the company’s valuation and earnings power.내러티브 업데이트 • Dec 25
BMY: Sector Perform View Will Limit Upside Despite Upcoming Earnings Focus
Analysts have nudged their fair value estimate for Bristol-Myers Squibb higher to about $38.41 from $35.86, reflecting a modestly richer future earnings multiple despite slightly weaker near term revenue growth and margin assumptions, and a new $45 price target under a Sector Perform view. Analyst Commentary Recent Street commentary frames Bristol-Myers Squibb as a lagging, but not broken, story within large cap biopharma.내러티브 업데이트 • Dec 11
BMY: Sector Outlook And Policy Shifts Will Shape Next Share Rerating
Analysts have nudged their price target for Bristol-Myers Squibb slightly higher to approximately $54 per share. This reflects a modestly richer future earnings multiple despite expectations for somewhat weaker revenue growth and profit margins, along with a more cautious Sector Perform stance from recent Street research.내러티브 업데이트 • Sep 04
Aging Demographics And Genomics Will Drive Healthcare Demand
Analysts maintained a cautious outlook on Bristol-Myers Squibb due to muted Cobenfy prescription trends and pipeline execution concerns, partially offset by optimism for upcoming Alzheimer’s data and future optionality, resulting in the consensus price target remaining steady at $53.00. Analyst Commentary Bearish analysts point to recent moderation in Cobenfy prescriptions for schizophrenia and maintain low growth expectations for this indication in the second half of 2025.주주 수익률
| BMY | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | 5.2% | -1.7% | 1.0% |
| 1Y | 47.7% | 47.4% | 19.1% |
수익률 대 산업: BMY은 지난 1년 동안 47.4%의 수익을 기록한 US Pharmaceuticals 산업과 동일한 성과를 보였습니다.
수익률 대 시장: BMY은 지난 1년 동안 19.1%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| BMY volatility | |
|---|---|
| BMY Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: BMY는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: BMY의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1887 | 32,500 | Chris Boerner | www.bms.com |
브리스톨-마이어스 스큅(Bristol-Myers Squibb Company)은 전 세계적으로 바이오의약품을 발굴, 개발, 라이선스 취득, 제조, 마케팅, 유통 및 판매하고 있습니다. 이 회사는 종양학, 혈액학, 면역학, 심혈관 및 신경과학 분야의 치료제를 제공합니다. 주요 제품으로는 항암 치료제인 ‘옵디보(Opdivo)’, 고형암 치료용 피하 주사형 PD-1 억제제인 ‘옵디보 콴티그(Opdivo Qvantig)’, 활동성 류마티스 관절염 및 건선성 관절염 치료제인 ‘오렌시아(Orencia)’, 절제 불가능하거나 전이성 흑색종 치료제인 ‘예르보이(Yervoy)’, 빈혈 치료제인 ‘레블로질(Reblozyl)’, 재발성 또는 난치성 대세포 B세포 림프종 치료제인 ‘브레얀지(Breyanzi)’, 절제 불가능하거나 전이성 흑색종 치료제인 ‘옵듀알라그(Opdualag)’, 그리고 증상성 폐쇄성 심근병증(HCM) 치료제인 ‘캠지오스(Camzyos)’ 등이 있습니다.
Bristol-Myers Squibb Company 기초 지표 요약
| BMY 기초 통계 | |
|---|---|
| 시가총액 | US$132.49b |
| 순이익 (TTM) | US$9.28b |
| 매출 (TTM) | US$49.19b |
14.4x
주가수익비율(P/E)2.7x
주가매출비율(P/S)BMY는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| BMY 손익계산서 (TTM) | |
|---|---|
| 매출 | US$49.19b |
| 매출원가 | US$13.94b |
| 총이익 | US$35.25b |
| 기타 비용 | US$25.97b |
| 순이익 | US$9.28b |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
Oct 29, 2026
| 주당순이익(EPS) | 4.54 |
| 총이익률 | 71.66% |
| 순이익률 | 18.87% |
| 부채/자본 비율 | 193.2% |
BMY의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Bristol-Myers Squibb 배당 일정 | |
|---|---|
| 배당락일 | Jul 02 2026 |
| 배당 지급일 | Aug 03 2026 |
| 배당락일까지 남은 일수 | 31 days |
| 배당 지급일까지 남은 일수 | 1 day |
BMY는 안정적으로 배당을 지급합니까?
BMY 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/31 04:10 |
| 종가 | 2026/07/31 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Bristol-Myers Squibb Company는 45명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Charles Butler | Barclays |